Influence of Androgen Suppression Therapy for Prostate Cancer on the Frequency and Timing of Fatal Myocardial Infarctions

Cited by (502)

Items 201–300 of 502

1. Assessment of endothelial dysfunction by flow‐mediated dilatation in men on long‐term androgen deprivation therapy for prostate cancer
   Stephen E. Gilbert, Garry Alan Tew, Liam Bourke, Edward Winter, Derek J. Rosario · 2013 · Experimental Physiology
2. High-risk prostate cancer
   M. Bolla, Camille Verry, Jean‐Alexandre Long · 2013 · Current Opinion in Urology
3. A 64-Year-Old Man With Low-Risk Prostate Cancer
   Martin George Sanda, I.D. Kaplan · 2009 · JAMA
4. Evolving Paradigm of Radiotherapy for High-Risk Prostate Cancer: Current Consensus and Continuing Controversies
   Aditya Juloori, Chirag Shah, Kevin L. Stephans, Andrew D. Vassil, Rahul D. Tendulkar · 2016 · Prostate Cancer
5. Abiraterone acetate plus prednisone in non-metastatic biochemically recurrent castration-naïve prostate cancer
   Nicholas Spetsieris, Myrto A Boukovala, Ioannis Alafis, John Warren Davis, Amado J. Zurita, Xuemei Wang, Shi‐Ming Tu, Brian Francis Chapin, Ana M. Aparicio, Paul Gettys Corn et al. · 2021 · European Journal of Cancer
6. Androgens regulate MMPs and the cellular processes of intimal hyperplasia
   Deidra J.H. Mountain, Brian M. Freeman, Stacy S. Kirkpatrick, John W. Beddies, Joshua D. Arnold, Michael B. Freeman, Mitchell H. Goldman, Scott L. Stevens, Frederick A. Klein, Oscar H. Grandas · 2013 · Journal of Surgical Research
7. Management of Prostate Cancer in Elderly Men
   Shelly X. Bian, Karen Elizabeth Hoffman · 2013 · Seminars in Radiation Oncology
8. Brachytherapy boost and cancer-specific mortality in favorable high-risk versus other high-risk prostate cancer
   Vinayak Muralidhar, Michael H. Xiang, Peter F. Orio, Neil E. Martin, Clair J. Beard, Felix Yi-Chung Feng, Karen Elizabeth Hoffman, Paul Linh Nguyen · 2016 · Journal of Contemporary Brachytherapy
9. Management of High-Risk Localized Prostate Cancer
   Ariel E. E. Marciscano, Matthew E. Hardee, Nicholas J Sanfilippo · 2011 · Advances in Urology
10. Severity of cardiovascular disease and health-related quality of life in men with prostate cancer: a longitudinal analysis from CaPSURE
    Lonneke Veronique van de Poll-Franse, Natalia Sadetsky, Lorna C. Kwan, Mark S. Litwin · 2008 · Quality of Life Research
11. Evaluating the Combined Effect of Comorbidity and Prostate-Specific Antigen Kinetics on the Risk of Death in Men After Prostate-Specific Antigen Recurrence
    Jennifer Yon-Li Wo, Ming‐Hui Chen, Paul Linh Nguyen, Andrew A. Renshaw, Marian J. Loffredo, Philip W. Kantoff, Anthony Victor D'Amico · 2009 · Journal of Clinical Oncology
12. Canadian Urological Association guideline on androgen deprivation therapy: Adverse events and management strategies
    Andrea Kokorovic, Alan So, Hosam A. Serag, Christopher French, Robert James Hamilton, Jason Izard, Jasmir Gopal Nayak, Frédéric Pouliot, Fred Saad C, Bobby Shayegan et al. · 2021 · Canadian Urological Association Journal
13. Clinical outcomes of helical tomotherapy for super-elderly patients with localized and locally advanced prostate cancer: comparison with patients under 80 years of age
    Noriyuki Okonogi, Hiroyuki Katoh, Hidemasa Kawamura, Tomoaki Tamaki, Takuya Kaminuma, Kazutoshi Murata, Yu Ohkubo, Yosuke Takakusagi, Masahiro Onishi, Tetsuo Sekihara et al. · 2015 · Journal of Radiation Research
14. Cancer-Specific Mortality Among Korean Men with Localized or Locally Advanced Prostate Cancer Treated with Radical Prostatectomy Versus Radiotherapy: A Multi-Center Study Using Propensity Scoring and Competing Risk Regression Analyses
    Kyo Chul Koo, Jin Seon Cho, Woo Jin Bang, Seung Hwan Lee, Sung Yong Cho, Sun Il Kim, Se Joong Kim, Koon Ho Rha, Sung Joon Hong, Byung Ha Chung · 2017 · Cancer Research and Treatment
15. Management of Advanced Prostate Cancer in Senior Adults: The New Landscape
    Matti Aapro · 2012 · The Oncologist
16. How to Improve the Quality of Life of Patients with Prostate Cancer Treated with Hormone Therapy?
    Fabio Turco, Lavinia Di Prima, Chiara Pisano, Stefano Poletto, Marco De Filippis, Veronica Crespi, Giovanni Farinea, Massimiliano Cani, Mariangela Calabrese, Isabella Saporita et al. · 2023 · Research and Reports in Urology
17. Cardiovascular risk in androgen suppression: underappreciated, under-researched and unresolved: Figure 1
    Liam Bourke, Tim Chico, Peter C. Albertsen, Freddie Charles Hamdy, Derek J. Rosario · 2011 · Heart
18. Enzalutamide inhibits testosterone-induced growth of human prostate cancer xenografts in zebrafish and can induce bradycardia
    Nicole Melong, Shelby L. Steele, Morgan MacDonald, Alice C. Holly, Colin C. Collins, Amina Zoubeidi, Jason N. Berman, Graham Dellaire · 2017 · Scientific Reports
19. Association between duration of gonadotrophin‐releasing hormone agonist use and cardiovascular risks: A population‐based competing‐risk analysis
    Jeffrey Shi Kai Chan, Pias Tang, Jeremy Man Ho Hui, Yan Hiu Athena Lee, Edward Christopher Dee, Kenrick Ng, Kang Liu, Gary Tse, Chi‐Fai Ng · 2022 · The Prostate
20. Survival Following Radiation and Androgen Suppression Therapy for Prostate Cancer in Healthy Older Men: Implications for Screening Recommendations
    Paul Linh Nguyen, Ming‐Hui Chen, Andrew A. Renshaw, Marian J. Loffredo, Philip W. Kantoff, Anthony Victor D'Amico · 2009 · International Journal of Radiation Oncology*Biology*Physics
21. Metabolic Syndrome in Prostate Cancer: Impact on Risk and Outcomes
    Fatima H. Karzai, Ravi Amrit Madan, William L. Dahut · 2016 · Future Oncology
22. Weight Gain on Androgen Deprivation Therapy: Which Patients Are at Highest Risk?
    Daniel Martin Seible, Xiangmei Gu, Andrew S. Hyatt, Clair J. Beard, Toni K. Choueiri, Jason Alexander Efstathiou, David Tomoaki Miyamoto, Тимур Митин, Neil E. Martin, Christopher J. Sweeney et al. · 2014 · Urology
23. Testosterone and cardiovascular disease – the controversy and the facts
    Abraham Morgentaler, Allison H. Feibus, Neil H Baum · 2015 · Postgraduate Medicine
24. Association of the Charlson comorbidity index and hypertension with survival in men with metastatic castration-resistant prostate cancer
    Jatinder Goyal, Gregory R. Pond, Matthew D. Galsky, Ryan Hendricks, Alexander Small, Che‐Kai Tsao, Guru Sonpavde · 2013 · Urologic Oncology Seminars and Original Investigations
25. Concept and viability of androgen annihilation for advanced prostate cancer
    James Lloyd Mohler · 2014 · Cancer
26. Systemic Treatment of Prostate Cancer in Elderly Patients: Current Role and Safety Considerations of Androgen-Targeting Strategies
    Myrto A Boukovala, Nicholas Spetsieris, Eleni Efstathiou · 2019 · Drugs & Aging
27. Dose-Escalated Radiotherapy for High-Risk Prostate Cancer: Outcomes in Modern Era With Short-Term Androgen Deprivation Therapy
    Stanley L. Liauw, Walter Michael Stadler, David Correa, Ralph R. Weichselbaum, Ashesh B. Jani · 2009 · International Journal of Radiation Oncology*Biology*Physics
28. Multiple Events of Fractures and Cardiovascular and Thromboembolic Disease Following Prostate Cancer Diagnosis: Results From the Population-Based PCBaSe Sweden
    Mieke Van Hemelrijck, Hans Garmo, Lars Holmberg, Pär E. Stattin, Jan Adolfsson · 2011 · European Urology
29. Radiation therapy and androgen deprivation in the management of high risk prostate cancer
    Alan Dal Pra, Fabio Cury, Luís Souhami · 2011 · International braz j urol
30. Are the adverse effects of glitazones linked to induced testosterone deficiency?
    Malcolm E. Carruthers, TR Trinick, Ewa Anita Jankowska, Abdulmaged M. Traish · 2008 · Cardiovascular Diabetology
31. Cardiovascular risk during androgen deprivation therapy for prostate cancer
    T. Hugh Jones · 2011 · BMJ
32. Effectiveness and adverse effects of hormonal therapy for prostate cancer: Japanese experience and perspective
    Mikio Namiki, Satoru Ueno, Yasuhide Kitagawa, Takashi Fukagai, Hideyuki Akaza · 2012 · Asian Journal of Andrology
33. Cardiovascular Preventive Care and Coordination of Care in Prostate Cancer Survivors: A Multi-Institutional Prospective Study
    Jordan A. Holmes, Roger F. Anderson, Leroy G. Hoffman, Timothy Norman Showalter, Mohit S. Kasibhatla, Sean P. Collins, Michael A. Papagikos, Brittany D. Barbosa, Kristy Alligood, L. Stravers et al. · 2018 · International Journal of Radiation Oncology*Biology*Physics
34. Population-Based Study of Cardiovascular Mortality Among Patients With Prostate Cancer Treated With Radical External Beam Radiation Therapy With and Without Adjuvant Androgen Deprivation Therapy at the British Columbia Cancer Agency
    Julian S. Kim, Moninder Vaid, Scott K. Tyldesley, Ryan R. Woods, Tom Pickles · 2010 · International Journal of Radiation Oncology*Biology*Physics
35. The Extrapituitary Effects of GnRH Antagonists and Their Potential Clinical Implications: A Narrated Review
    Orkun Tan, Bruce Richard Carr, Victor E. Beshay, Orhan Bükülmez · 2012 · Reproductive Sciences
36. Predictors of Androgen Deprivation Therapy Efficacy Combined With Prostatic Irradiation: The Central Role of Tumor Stage and Radiation Dose
    Scott Williams, Mark K. Buyyounouski, Larry Llyn Kestin, Gillian M. Duchesne, Tom Pickles · 2010 · International Journal of Radiation Oncology*Biology*Physics
37. Does Neoadjuvant Androgen Deprivation Therapy Before Primary Whole Gland Cryoablation of the Prostate Affect the Outcome?
    Erik T. Grossgold, Robert W Given, Herbert C. Ruckle, J. Stephen Jones · 2013 · Urology
38. Pretreatment Serum Testosterone and Androgen Deprivation: Effect on Disease Recurrence and Overall Survival in Prostate Cancer Patients Treated With Brachytherapy
    Al V. Taira, Gregory Stephen Merrick, Robert W. Galbreath, Wayne M. Butler, Kent E. Wallner, Zachariah A. Allen, Jonathan H. Lief, Edward Adamovich · 2008 · International Journal of Radiation Oncology*Biology*Physics
39. Cardiovascular Toxicity of Androgen Deprivation Therapy: A New Door Opens
    Shabbir M.H. Alibhai · 2011 · Journal of Clinical Oncology
40. A Repurposing Programme Evaluating Transdermal Oestradiol Patches for the Treatment of Prostate Cancer Within the PATCH and STAMPEDE Trials: Current Results and Adapting Trial Design
    Duncan Charles Gilbert, Matthew Guy Nankivell, Hannah L. Rush, Noel William Clarke, Stephen A. Mangar, Abdulla A. Alhasso, Stuart David Rosen, Roger Clive Kockelbergh, Subramanian Kanaga Sundaram, Sanjay Dixit et al. · 2023 · Clinical Oncology
41. Expanded risk groups help determine which prostate radiotherapy sub-group may benefit from adjuvant androgen deprivation therapy
    Matthew R. Beasley, Scott Williams, Tom Pickles, The BCCA Prostate Outcomes Unit · 2008 · Radiation Oncology
42. Effect of Androgen Deprivation Therapy on Metabolic Complications and Cardiovascular Risk
    Chiara Melloni, Adam J. Nelson · 2019 · Journal of Cardiovascular Translational Research
43. Dose‐escalated radiation therapy for intermediate‐risk prostate cancer
    Stanley L. Liauw, Janine Fricano, David Correa, Ralph R. Weichselbaum, Ashesh B. Jani · 2009 · Cancer
44. Regarding the Influence of Adjuvant Suppression Therapy for Prostate Cancer on the Frequency and Timing of Fatal Myocardial Infarction: How Real Is the Risk?
    Mack Roach · 2007 · Journal of Clinical Oncology
45. Physical Activity and Genitourinary Cancer Survivorship
    Daniel Abido Galvao, Dennis R. Taaffe, Nigel A. Spry, Robert Usher Newton · 2010 · Recent results in cancer research/Recent Results in Cancer Research
46. Risk of cardiovascular mortality with androgen deprivation therapy in prostate cancer: A secondary analysis of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Randomized Controlled Trial
    Santino S. Butler, Brandon Arvin Virgil Mahal, Javid J. Moslehi, Anju Nohria, Edward Christopher Dee, Rishi Makkar, Amanda Whitbeck, Janet Wangoe, Kent William Mouw, Paul Linh Nguyen et al. · 2021 · Cancer
47. Role of hormonal therapy for prostate cancer: perspective from Japanese experiences.
    Mikio Namiki, Satoru Ueno, Yasuhide Kitagawa · 2012 · PubMed Central
48. Impact of Neoadjuvant Prostate-Specific Antigen Kinetics on Biochemical Failure and Prostate Cancer Mortality: Results From a Prospective Patient Database
    Marcus Foo, Mariel S. Lavieri, Tom Pickles · 2013 · International Journal of Radiation Oncology*Biology*Physics
49. Survival following primary androgen deprivation therapy for localized intermediate- or high-risk prostate cancer: comparison with the life expectancy of the age-matched normal population
    Kazuhiro Matsumoto, Masayuki Hagiwara, Nobuyuki Tanaka, Nozomi Hayakawa, Masaru Ishida, Akiharu Ninomiya, Yosuke Nakajima, So Nakamura · 2014 · Medical Oncology
50. Neoadjuvant hormonal therapy and external-beam radiotherapy versus external-beam irradiation alone for prostate cancer
    Michael Pinkawa, Marc Dieter Piroth, Branka Asadpour, Bernd Gagel, Karin Fischedick, Jaroslav Siluschek, Mareike Kehl, Barbara Krenkel, Michael J. Eble · 2009 · Strahlentherapie und Onkologie
51. Gonadotropin-Releasing Hormone Agonists and the Risks of Type 2 Diabetes and Cardiovascular Disease in Men with Prostate Cancer
    Philip James Saylor, Nancy Lynn Keating, Stephen J. Freedland, Matthew R. Smith · 2011 · Drugs
52. Effects of Androgen Deprivation Therapy on Prostate Cancer Outcomes According to Competing Event Risk: Secondary Analysis of a Phase 3 Randomised Trial
    Loren K. Mell, Stephanie L. Pugh, Christopher Uwe Jones, Tyler J. Nelson, Kaveh Zakeri, Brent Shane Rose, Kenneth Lee Zeitzer, Elizabeth Gore, Jean-Paul Bahary, Luís Souhami et al. · 2023 · European Urology
53. The side effects of hormonal therapy at the patients with carcinoma of prostate cancer
    Ewa Ziółkowska, Małgorzata Zarzycka, Tomasz Wiśniewski, Agnieszka Żyromska · 2012 · Współczesna Onkologia
54. Effects of androgen-deprivation therapy on hypercoagulability in prostate cancer patients: A prospective, longitudinal study
    Harmanpreet Kaur, David Robert Siemens, Angela M. Black, Sylvia Robb, Spencer Barr, Charles H. Graham, Maha Othman · 2017 · Canadian Urological Association Journal
55. Management of prostate cancer in older patients
    Shintaro Narita, Shingo Hatakeyama, Shinichi Sakamoto, Takuma Kato, Juichi Inokuchi, Yoshiyuki Matsui, Hiroshi Kitamura, Hiroyuki Nishiyama, Tomonori Habuchi · 2022 · Japanese Journal of Clinical Oncology
56. Cardiovascular Effects of Androgen Deprivation Therapy in Prostate Cancer Patients: A Systematic Review
    Meghana Kakarla, Musa Ausaja Gambo, Mustafa Yousri Salama, Nathalie Haidar Ismail, Pardis Tavalla, Pulkita Uppal, Shaza A Mohammed, Shriya Rajashekar, Suganya Giri Ravindran, Pousette Hamid · 2022 · Cureus
57. Long-Term Follow-Up of a Prospective Trial of Trimodality Therapy of Weekly Paclitaxel, Radiation, and Androgen Deprivation in High-Risk Prostate Cancer With or Without Prior Prostatectomy
    Arif Hussain, Yin Wu, Alireza Mirmiran, Steven J. DiBiase, Olga G. Goloubeva, Benjamin B. Bridges, Heather Dorothy Mannuel, Christine A. Engstrom, Nancy Ann Dawson, Pradip P. Amin et al. · 2010 · International Journal of Radiation Oncology*Biology*Physics
58. Risk of cardiovascular events in men on abiraterone or enzalutamide combined with GnRH agonists: nation-wide, population-based cohort study in Sweden
    Gincy George, Hanna Vikman, Rolf Gedeborg, Ingela Franck Lissbrant, Hans Garmo, Johan Styrke, Mieke Van Hemelrijck, Pär E. Stattin · 2021 · Acta Oncologica
59. Does Timing of Androgen Deprivation Influence Radiation-Induced Toxicity? A Secondary Analysis of Radiation Therapy Oncology Group Protocol 9413
    Daniel Taussky, Kyounghwa Bae, Jean-Paul Bahary, Mack Roach, C.A. Lawton, William U. Shipley, Howard Mark Sandler · 2008 · Urology
60. Urological Oncology: Prostate Cancer
    Patrick C. Walsh · 2010 · The Journal of Urology
61. Novel hormone therapy and coordination of care in high-risk biochemically recurrent prostate cancer
    Jason Alexander Efstathiou, Alicia Katherine Morgans, Christopher S. Bland, Neal D. Shore · 2023 · Cancer Treatment Reviews
62. Primary Intermittent Androgen Deprivation As Initial Therapy for Men with Newly Diagnosed Prostate Cancer
    Mark Creamer Scholz, Richard Y. Lam, Stephen Bruce Strum, Dean J. LaBarba, Lauren K. Becker, Patricia J. Chang, Nojan Farhoumand, Robert I. Jennrich · 2011 · Clinical Genitourinary Cancer
63. Duration of Androgen Deprivation Therapy for High-Risk Prostate Cancer: Application of Randomized Trial Data in a Tertiary Referral Cancer Center
    Vinayak Muralidhar, Meredith M. Regan, Lillian L. Werner, Mari Nakabayashi, Carolyn P. Evan, Joaquim Bellmunt B, Toni K. Choueiri, Aymen A. Elfiky, Lauren C. Harshman, Rana R. McKay et al. · 2015 · Clinical Genitourinary Cancer
64. Radical Prostatectomy in Korean Men Aged 75-Years or Older: Safety and Efficacy in Comparison with Patients Aged 65–69 Years
    Jae Hyun Ryu, Yun Beom Kim, Tae Young Jung, Sun Il Kim, Seok‐Soo Byun, Dong Deuk Kwon, Duk Yoon Kim, Tae Hee Oh, Tag Keun Yoo, Woo Jin Ko · 2016 · Journal of Korean Medical Science
65. Androgen Suppression Strategies for Prostate Cancer: Is There an Ideal Approach?
    Mohamed Ismail, Matthew C. Ferroni, Leonard G. Gomella · 2011 · Current Urology Reports
66. Influence of age on androgen deprivation therapy-associated Alzheimer’s disease
    Kevin Thomas Nead, Greg Gaskin, Cariad Chester, Samuel D. Swisher-McClure, Joel T. Dudley, Nicholas James Leeper, Nigam Haresh Shah · 2016 · Scientific Reports
67. The impact of prostate cancer and hormonal therapy on bone.
    Gerald L. Andriole · 2009 · Europe PMC (PubMed Central)
68. Recommandations pour la prise en charge du cancer de la prostate chez l’homme âgé : un travail du comité de cancérologie de l’association française d’urologie
    Pierre Mongiat-Artus, Michaël Peyromaure, Pierre M. Richaud, Jean‐Pierre Droz, M. Rainfray, Claude Jeandel, Xavier Rébillard, J.-L. Moreau, Jean‐Louis Davin, Laurent Salomon et al. · 2009 · The French Journal of Urology
69. Prostate Brachytherapy in Men ≥75 Years of Age
    Gregory Stephen Merrick, Kent E. Wallner, Robert W. Galbreath, Wayne M. Butler, Sarah G. Brammer, Zachariah A. Allen, Edward Adamovich · 2008 · International Journal of Radiation Oncology*Biology*Physics
70. Clinical studies investigating the use of leuprorelin for prostate cancer in Asia
    Byung Ha Chung, Shigeo Horie, Edmund Chiong · 2019 · Prostate International
71. The Brain, the Penis and Steroid Hormones: Clinical Correlates with Endothelial Dysfunction
    Abdulmaged M. Traish, Hilal Abu-Zahra, André T. Guay · 2008 · Current Pharmaceutical Design
72. Cardiovascular Disease Associated With Androgen-Deprivation Therapy: Time to Give It Due Respect
    Shehzad Sultan Basaria · 2015 · Journal of Clinical Oncology
73. Androgen-deprivation Therapy and Cardiovascular Harm: Let's Not Throw Out the Baby with the Bathwater
    Paul Linh Nguyen · 2013 · European Urology
74. Cardio-oncology in advanced prostate cancer
    Kenneth Chen, Ting Hong Wong, Yu Guang Tan, Kae Jack Tay, Wei Chong Tan, Johan Chan, Henry Sun Sien Ho, Christopher W.S. Cheng, Jeremy Yuen‐Chun Teoh, Peter Ka‐Fung Chiu et al. · 2024 · Frontiers in Oncology
75. Association of Gonadotropin-Releasing Hormone Agonists for Prostate Cancer With Cardiovascular Disease Risk and Hypertension in Men With Diabetes
    E Lin, Hans Garmo, Mieke Van Hemelrijck, Björn Zethelius, Pär E. Stattin, Emil Hagström, Jan Adolfsson, Danielle Crawley · 2022 · JAMA Network Open
76. Induced testosterone deficiency: from clinical presentation of fatigue, erectile dysfunction and muscle atrophy to insulin resistance and diabetes
    George W. Yu, Abdulmaged M. Traish · 2011 · Hormone Molecular Biology and Clinical Investigation
77. Risk of All-Cause and Prostate Cancer–Specific Mortality After Brachytherapy in Men With Small Prostate Size
    Paul Linh Nguyen, Ming H. Chen, Toni K. Choueiri, Karen Elizabeth Hoffman, Jim C. Hu, Neil E. Martin, Clair J. Beard, Daniel E. Dosoretz, Brian Joseph Moran, Michael J. Katin et al. · 2010 · International Journal of Radiation Oncology*Biology*Physics
78. Mortalidad cardiovascular asociada a la deprivación androgénica en pacientes con cáncer de próstata
    Juan Ignacio Monzó Gardiner, Felipe Herranz-Amo · 2015 · Actas Urológicas Españolas
79. Cardiovascular Complications of Prostate Cancer Therapy
    Courtney M. Campbell, Kathleen W. Zhang, Andrew Collier, Mark David Linch, Adam Christopher Calaway, Lee Evan Ponsky, Avirup Guha, Arjun Kumar Ghosh · 2020 · Current Treatment Options in Cardiovascular Medicine
80. COMPLICATIONS OF ANDROGEN‐DEPRIVATION THERAPY IN PROSTATE CANCER: THE OTHER SIDE OF THE COIN
    Paul Hoffmann, Claude Schulman · 2008 · British Journal of Urology
81. Can Intermittent Hormone Therapy Fulfil its Promise?
    Ulf W. Tunn · 2008 · European Urology Supplements
82. Toward the Optimal Use of Androgen Suppression Therapy in the Radiotherapeutic Management of Prostate Cancer
    Anthony Victor D'Amico · 2006 · Journal of Clinical Oncology
83. Androgen-deprivation therapy and risk of death from cardio-vascular disease in prostate cancer patients: a nationwide lithuanian population-based cohort study
    Justinas Jonušas, Mingailė Drevinskaitė, Aušvydas Patašius, Marius Kinčius, Ernestas Janulionis, Giedrė Smailytė · 2022 · The Aging Male
84. Early Versus Delayed Androgen Deprivation Therapy for Biochemical Recurrence After Local Curative Treatment in Non-Metastatic Hormone-Sensitive Prostate Cancer: A Systematic Review of the Literature
    Muneeb Uddin Karim, Steven Tisseverasinghe, Rodrigo Cartes, Constanza Martínez, Boris Bahoric, Tamim Mohammad Niazi · 2025 · Cancers
85. UPDATE – Canadian Urological Association guideline on androgen deprivation therapy: Adverse events and management strategies (Full-text)
    Andrea Kokorovic, Alan So, Hosam A. Serag, Christopher French, Robert James Hamilton, Jason Izard, Jasmir Gopal Nayak, Frédéric Pouliot, Fred Saad C, Bobby Shayegan et al. · 2022 · Canadian Urological Association Journal
86. Radical Radiotherapy for High-Risk Prostate Cancer in Older Men
    Heather Ann Payne, Simon R. Hughes · 2012 · The Oncologist
87. Risk of diabetes complications among those with diabetes receiving androgen deprivation therapy for localized prostate cancer
    Marie C. Bradley, Yingjun Zhou, Andrew N. Freedman, Marianne Ulcickas Yood, Charles P. Quesenberry, Reina Haque, Stephen K. Van Den Eeden, Andrea E. Cassidy‐Bushrow, David S. Aaronson, Arnold L. Potosky · 2018 · Cancer Causes & Control
88. Cardiovascular complications of treatment for prostate cancer
    Vera Vaz Ferreira, Inês Ângelo, Boban Thomas, Arjun Kumar Ghosh · 2022 · British Journal of Hospital Medicine
89. The changing face of hormonal therapy for prostate cancer
    Boštjan Šeruga, Ian F. Tannock · 2008 · Annals of Oncology
90. Renal and Cardiovascular Toxicities by New Systemic Treatments for Prostate Cancer
    Giuseppe Saltalamacchia, Mara Frascaroli, Antônio Bernardo, Erica Quaquarini · 2020 · Cancers
91. Metabolic Complications and Increased Cardiovascular Risks as a Result of Androgen Deprivation Therapy in Men with Prostate Cancer
    Bhavin R. Shastri, Subhashini Yaturu · 2011 · Prostate Cancer
92. Don’t think once, think twice! the cardiovascular effects of androgen deprivation therapy
    Edward Jefferies, Ramesh Thurairaja, Raj A. Persad, Ronak Rajani, J. Phull, Amit K. Bahl · 2011 · British Journal of Urology
93. Radical prostatectomy for clinically localized prostate cancer in patients aged 75 years or older: comparison with primary androgen deprivation therapy
    Jae Hyun Ryu, Sang Jin Kim, Yun Beom Kim, Tae Young Jung, Woo Jin Ko, Sun Il Kim, Duk Yoon Kim, Tae Hee Oh, Kyong Tae Moon, Hee Ju Cho et al. · 2017 · The Aging Male
94. Short-term versus long-term hormone therapy plus radiotherapy or prostatectomy for prostate cancer: a systematic review and meta-analysis
    Zhirui Zhou, Xiao‐Dong Zhu, Jun Xia, Zhang‐Yu Zou, Song Qu, Xian‐Tao Zeng, Zhi Mao, Zhongguo Liang · 2013 · Journal of Cancer Research and Clinical Oncology
95. Local delivery of hormonal therapy with silastic tubing for prevention and treatment of breast cancer
    Jeenah Park, Scott Thomas, Allison Y. Zhong, Alan R. Wolfe, Gregor Krings, Manuela Terranova-Barberio, Nela Pawłowska, Leslie Z. Benet, Pamela N. Münster · 2018 · Scientific Reports
96. 2020 Korean guidelines for the management of metastatic prostate cancer
    In-Ho Kim, Sang Joon Shin, Byung Woog Kang, JiHoon Kang, Dalyong Kim, Miso Kim, Jin Young Kim, Chan Kyu Kim, Hee Jun Kim, Chi Hoon Maeng et al. · 2020 · The Korean Journal of Internal Medicine
97. Serum testosterone level after intensity-modulated radiotherapy in low-risk prostate cancer patients: does testicular dose correlate with testosterone level?
    Hiromichi Ishiyama, Bin Sing Teh, Arnold C. Paulino, S.T. Yogeswaren, Wei-yuan Mai, Bo Xu, Edward Brian Butler · 2012 · Journal of Radiation Oncology
98. Prostate cancer update: 2007
    Amy Lin, Eric Jay Small · 2008 · Current Opinion in Oncology
99. Cardiovascular Disease Risk Factors: How Relevant in African Men With Prostate Cancer Receiving Androgen-Deprivation Therapy?
    Okon Essien, Iya Eze Bassey, Rebecca Mtaku Gali, A. E. Udoh, Uwem Okon Akpan, Enakirerhi E. Glen · 2016 · Journal of Global Oncology
100. Screening and Treating Prostate Cancer in the Older Patient: Decision Making Across the Clinical Spectrum
     Alicia Katherine Morgans, William Dale, Alberto Briganti · 2017 · American Society of Clinical Oncology Educational Book